These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36178585)

  • 1. Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review.
    van der Horst-Bruinsma IE; Robinson PC; Favalli EG; Verbraak FD; Kim M; Kumke T; Bauer L; Hoepken B; Deodhar A
    Rheumatol Ther; 2022 Dec; 9(6):1481-1497. PubMed ID: 36178585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
    van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
    van der Horst-Bruinsma IE; van Bentum RE; Verbraak FD; Deodhar A; Rath T; Hoepken B; Irvin-Sellers O; Thomas K; Bauer L; Rudwaleit M
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211003803. PubMed ID: 33854572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
    Robinson PC; Maksymowych WP; Gensler LS; Hall S; Rudwaleit M; Hoepken B; Bauer L; Kumke T; Kim M; de Peyrecave N; Deodhar A
    ACR Open Rheumatol; 2022 Sep; 4(9):794-801. PubMed ID: 35733363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
    Marin J; Acosta Felquer ML; Soriano ER
    Open Access Rheumatol; 2018; 10():33-41. PubMed ID: 29765257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol for treating axial spondyloarthritis.
    Desmarais J; Beier S; Deodhar A
    Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
    Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
    Landewé R; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch F; Gaffney K; Bauer L; Hoepken B; de Peyrecave N; Thomas K; Gensler LS
    Rheumatol Ther; 2020 Sep; 7(3):581-599. PubMed ID: 32529495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
    Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
    Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
    Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
    van der Heijde D; Gensler LS; Maksymowych WP; Landewé R; Rudwaleit M; Bauer L; Kumke T; Kim M; Auteri SE; Hoepken B; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
    Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
    Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with acute anterior uveitis history in patients with axial spondyloarthritis: Results of a longitudinal study.
    Cinakli H; Ediboglu ED; Solmaz D; Akar S
    Int J Rheum Dis; 2024 Mar; 27(3):e15076. PubMed ID: 38454194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred With Anterior Uveitis and Chronic Back Pain: The SpEYE Study.
    van Bentum RE; Verbraak FD; Wolf S; Ongkosuwito J; Boers M; Tan HS; van der Horst-Bruinsma IE
    J Rheumatol; 2022 Jul; 49(7):680-687. PubMed ID: 35169057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
    Baraliakos X; Kruse S; Auteri SE; de Peyrecave N; Nurminen T; Kumke T; Hoepken B; Braun J
    Rheumatology (Oxford); 2022 Jul; 61(7):2875-2885. PubMed ID: 34791107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol in the treatment of axial spondyloarthritis.
    Anderson E; Beier S; Desmarais J
    Immunotherapy; 2024 Mar; ():. PubMed ID: 38530074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.
    van der Heijde D; Braun J; Rudwaleit M; Purcaru O; Kavanaugh AF
    RMD Open; 2018; 4(1):e000659. PubMed ID: 29670761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
    Katsifis G; Theodoridou A; Bounas A; Georgiou P; Sfikakis P; Fragiadaki K; Dimitroulas T; Mole E; Bauer L; Kumke T; Hoepken B
    Mediterr J Rheumatol; 2022 Mar; 33(Suppl 1):162-172. PubMed ID: 36127922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.